Observational Usage Study of Faslodex in Patients Suffering From Initial Breast Cancer in France
NCT ID: NCT00681369
Last Updated: 2011-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
217 participants
OBSERVATIONAL
2007-05-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Quality Of Life While Receiving Faslodex
NCT00643513
Faslodex 500mg Multiple Dose Tolerability Study in BC Patients
NCT00328120
A Clinical Trial to Compare Efficacy and Tolerability of Faslodex With Arimidex in Patients With Advanced Breast Cancer
NCT00274469
Second Line Breast Cancer Trial
NCT00635713
Faslodex Post Marketing Surveillance
NCT00860561
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Patients suffering from initial breast cancer, treated with Faslodex, treatment which was stopped during 2007
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
AstraZeneca
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alain FLINOIS
Role: PRINCIPAL_INVESTIGATOR
TNS Healthcare - France138, avenue Marx Dormoy92120 Montrouge
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIS-OFR-FAS-2007/1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.